Paul Tudor Jones's GILD Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 58,369 shares of Gilead Sciences, Inc. (GILD) worth $8.13 M, representing 0.02% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 273,136 shares. Largest reduction occurred in Q3 2024, reducing 521,017 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +58,369 | New Buy | 58,369 | $139.37 |
| Q4 2025 | -128,173 | Sold Out | 0 | $0.00 |
| Q3 2025 | +110,380 | Add 620.36% | 128,173 | $111.00 |
| Q2 2025 | -23,936 | Reduce 57.36% | 17,793 | $110.87 |
| Q1 2025 | -120,644 | Reduce 74.30% | 41,729 | $112.05 |
| Q4 2024 | +162,373 | New Buy | 162,373 | $92.37 |
| Q3 2024 | -521,017 | Sold Out | 0 | $0.00 |
| Q2 2024 | +210,451 | Add 67.76% | 521,017 | $68.61 |
| Q1 2024 | +273,136 | Add 729.72% | 310,566 | $73.25 |
| Q4 2023 | +37,430 | New Buy | 37,430 | $81.01 |
| Q3 2023 | -3,874 | Sold Out | 0 | $0.00 |
| Q2 2023 | +3,874 | New Buy | 3,874 | $77.07 |
| Q2 2022 | -132,517 | Sold Out | 0 | $0.00 |
| Q1 2022 | +49,642 | Add 59.90% | 132,517 | $59.45 |
| Q4 2021 | +77,289 | Add 1383.62% | 82,875 | $72.62 |
| Q3 2021 | +5,586 | New Buy | 5,586 | $69.82 |
| Q2 2021 | -34,755 | Sold Out | 0 | $0.00 |
| Q1 2021 | +34,755 | New Buy | 34,755 | $64.62 |
| Q4 2020 | -25,698 | Sold Out | 0 | $0.00 |
| Q3 2020 | +25,698 | New Buy | 25,698 | $63.20 |
| Q2 2020 | -10,978 | Sold Out | 0 | $0.00 |
| Q1 2020 | -61,957 | Reduce 84.95% | 10,978 | $74.79 |
| Q4 2019 | +28,123 | Add 62.76% | 72,935 | $64.98 |
| Q3 2019 | -30,969 | Reduce 40.87% | 44,812 | $63.38 |
| Q2 2019 | -45,338 | Reduce 37.43% | 75,781 | $67.56 |
| Q1 2019 | +65,481 | Add 117.69% | 121,119 | $65.01 |
| Q4 2018 | +35,364 | Add 174.43% | 55,638 | $62.55 |
| Q3 2018 | -7,581 | Reduce 27.22% | 20,274 | $77.19 |
| Q2 2018 | +3,764 | Add 15.62% | 27,855 | $70.83 |
| Q1 2018 | +20,144 | Add 510.36% | 24,091 | $75.38 |
| Q4 2017 | +3,947 | New Buy | 3,947 | $71.70 |
| Q2 2017 | -20,709 | Sold Out | 0 | $0.00 |
| Q1 2017 | +9,308 | Add 81.64% | 20,709 | $67.94 |
| Q4 2016 | +8,601 | Add 307.18% | 11,401 | $71.57 |
| Q3 2016 | -10,951 | Reduce 79.64% | 2,800 | $79.29 |
| Q2 2016 | -27,598 | Reduce 66.74% | 13,751 | $83.41 |
| Q1 2016 | +24,735 | Add 148.88% | 41,349 | $91.85 |
| Q4 2015 | +9,314 | Add 127.59% | 16,614 | $101.18 |
| Q3 2015 | -3,080 | Reduce 29.67% | 7,300 | $98.22 |
| Q2 2015 | +3,845 | Add 58.84% | 10,380 | $117.05 |
| Q1 2015 | -102,837 | Reduce 94.02% | 6,535 | $98.09 |
| Q4 2014 | +79,127 | Add 261.62% | 109,372 | $94.26 |
| Q3 2014 | +20,941 | Add 225.08% | 30,245 | $106.46 |
| Q2 2014 | -1,501 | Reduce 13.89% | 9,304 | $82.87 |
| Q1 2014 | +2,808 | Add 35.11% | 10,805 | $70.89 |
| Q4 2013 | +7,997 | New Buy | 7,997 | $75.15 |
| Q3 2013 | -9,200 | Sold Out | 0 | $0.00 |
| Q2 2013 | +9,200 | Add 0.00% | 9,200 | $51.30 |
Paul Tudor Jones's Gilead Sciences Investment FAQs
Paul Tudor Jones first purchased Gilead Sciences, Inc. (GILD) in Q2 2013, acquiring 9,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Gilead Sciences, Inc. (GILD) for 48 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Gilead Sciences, Inc. (GILD) was in Q1 2024, adding 310,566 shares worth $22.75 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 58,369 shares of Gilead Sciences, Inc. (GILD), valued at approximately $8.13 M.
As of the Q1 2026 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Gilead Sciences, Inc. (GILD) was 521,017 shares, as reported at the end of Q2 2024.